Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.

Hoyle, Alex P; Ali, Adnan; James, Nicholas D; Cook, Adrian; Parker, Christopher C; de Bono, Johann S; Attard, Gerhardt; Chowdhury, Simon; Cross, William R; Dearnaley, David P; +16 more... Brawley, Christopher D; Gilson, Clare; Ingleby, Fiona; Gillessen, Silke; Aebersold, Daniel M; Jones, Rob J; Matheson, David; Millman, Robin; Mason, Malcolm D; Ritchie, Alastair WS; Russell, Martin; Douis, Hassan; Parmar, Mahesh KB; Sydes, Matthew R; Clarke, Noel W; STAMPEDE Investigators; (2019) Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. European urology, 76 (6). pp. 719-728. ISSN 0302-2838 DOI: https://doi.org/10.1016/j.eururo.2019.08.006

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/j.eururo.2019.08.006

Abstract

Share

Download

Filename: Abiraterone-in-High-and-Low-risk-Metastatic-Hormone-sensitive-Prostate-Cancer.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar